{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:13:55Z","timestamp":1779293635359,"version":"3.51.4"},"reference-count":125,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"The Roman-Epstein Research Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1111\/apt.13833","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T03:17:04Z","timestamp":1477365424000},"page":"1168-1182","source":"Crossref","is-referenced-by-count":35,"title":["Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression"],"prefix":"10.1111","volume":"44","author":[{"given":"Y.","family":"Ilan","sequence":"first","affiliation":[{"name":"Gastroenterology and Liver Units; Department of Medicine; Hadassah Hebrew University Medical Center; Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"10.1111\/apt.13833-BIB0001|apt13833-cit-0001","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrgastro.2013.183","article-title":"NAFLD, NASH and liver cancer","volume":"10","author":"Michelotti","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0002|apt13833-cit-0002","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/1535370215579161","article-title":"Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine","volume":"240","author":"Noureddin","year":"2015","journal-title":"Exp Biol Med"},{"key":"10.1111\/apt.13833-BIB0003|apt13833-cit-0003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","article-title":"From NAFLD to NASH to cirrhosis-new insights into disease mechanisms","volume":"10","author":"Wree","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1 Suppl","key":"10.1111\/apt.13833-BIB0004|apt13833-cit-0004","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jhep.2015.02.041","article-title":"Current efforts and trends in the treatment of NASH","volume":"62","author":"Ratziu","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/apt.13833-BIB0005|apt13833-cit-0005","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.2147\/DDDT.S64877","article-title":"Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options","volume":"9","author":"Milic","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1111\/apt.13833-BIB0006|apt13833-cit-0006","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MOG.0000000000000060","article-title":"State of the art: treatment of nonalcoholic steatohepatitis","volume":"30","author":"Pearlman","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0007|apt13833-cit-0007","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2013.41","article-title":"Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis","volume":"10","author":"Anstee","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0008|apt13833-cit-0008","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","article-title":"Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0009|apt13833-cit-0009","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/hep.24747","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis","volume":"55","author":"Ratziu","year":"2012","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0010|apt13833-cit-0010","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0011|apt13833-cit-0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.gastro.2014.04.046","article-title":"No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial","volume":"147","author":"Sanyal","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0012|apt13833-cit-0012","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","article-title":"Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study","volume":"47","author":"Zelber-Sagi","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/apt.13833-BIB0013|apt13833-cit-0013","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.13833-BIB0014|apt13833-cit-0014","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0015|apt13833-cit-0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/dc10-1067","article-title":"Cohort study of pioglitazone and cancer incidence in patients with diabetes","volume":"34","author":"Ferrara","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1111\/apt.13833-BIB0016|apt13833-cit-0016","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/apt.13833-BIB0017|apt13833-cit-0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.gastro.2015.11.017","article-title":"End points must be clinically meaningful for drug development in nonalcoholic fatty liver disease","volume":"150","author":"Sanyal","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0018|apt13833-cit-0018","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jama.297.8.842","article-title":"Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis","volume":"297","author":"Bjelakovic","year":"2007","journal-title":"JAMA"},{"key":"10.1111\/apt.13833-BIB0019|apt13833-cit-0019","doi-asserted-by":"crossref","first-page":"c3659","DOI":"10.1136\/bmj.c3659","article-title":"Migraine and risk of haemorrhagic stroke in women: prospective cohort study","volume":"341","author":"Kurth","year":"2010","journal-title":"BMJ"},{"key":"10.1111\/apt.13833-BIB0020|apt13833-cit-0020","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein","year":"2011","journal-title":"JAMA"},{"issue":"32 Suppl. 7","key":"10.1111\/apt.13833-BIB0021|apt13833-cit-0021","first-page":"S52","article-title":"Inflammation and endoplasmic reticulum stress in obesity and diabetes","volume":"2008","author":"Hotamisligil","year":"2005","journal-title":"Int J Obes"},{"key":"10.1111\/apt.13833-BIB0022|apt13833-cit-0022","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1111\/apt.13833-BIB0023|apt13833-cit-0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00008480-200104000-00016","article-title":"Chronic acetaminophen overdosing in children: risk assessment and management","volume":"13","author":"Sztajnkrycer","year":"2001","journal-title":"Curr Opin Pediatr"},{"key":"10.1111\/apt.13833-BIB0024|apt13833-cit-0024","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","article-title":"Decoding cell death signals in liver inflammation","volume":"59","author":"Brenner","year":"2013","journal-title":"J Hepatol"},{"key":"10.1111\/apt.13833-BIB0025|apt13833-cit-0025","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cld.2012.05.002","article-title":"Mechanisms of disease progression in NASH: new paradigms","volume":"16","author":"Bohinc","year":"2012","journal-title":"Clin Liver Dis"},{"key":"10.1111\/apt.13833-BIB0026|apt13833-cit-0026","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2011.10.017","article-title":"Recent trends in antibody-based oncologic imaging","volume":"315","author":"Kaur","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1111\/apt.13833-BIB0027|apt13833-cit-0027","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"Du Plessis","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0028|apt13833-cit-0028","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.2337\/diabetes.51.10.2968","article-title":"The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects","volume":"51","author":"Yu","year":"2002","journal-title":"Diabetes"},{"key":"10.1111\/apt.13833-BIB0029|apt13833-cit-0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1111\/apt.13833-BIB0030|apt13833-cit-0030","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1172\/JCI25604","article-title":"Farnesoid X receptor is essential for normal glucose homeostasis","volume":"116","author":"Ma","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1111\/apt.13833-BIB0031|apt13833-cit-0031","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1111\/apt.13833-BIB0032|apt13833-cit-0032","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/hep.22668","article-title":"Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation","volume":"48","author":"Wagner","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0033|apt13833-cit-0033","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0034|apt13833-cit-0034","doi-asserted-by":"crossref","first-page":"28","DOI":"10.12703\/P7-28","article-title":"Recent advances in understanding\/management of non-alcoholic steatohepatitis","volume":"7","author":"Pacana","year":"2015","journal-title":"F1000prime Rep"},{"key":"10.1111\/apt.13833-BIB0035|apt13833-cit-0035","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.2337\/dc11-0093","article-title":"Effects of the new dual PPAR alpha\/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism","volume":"34","author":"Cariou","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1111\/apt.13833-BIB0036|apt13833-cit-0036","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/hep.22334","article-title":"Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice","volume":"48","author":"Qin","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0037|apt13833-cit-0037","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1172\/JCI27955","article-title":"PPAR delta: a dagger in the heart of the metabolic syndrome","volume":"116","author":"Barish","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1111\/apt.13833-BIB0038|apt13833-cit-0038","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0b013e32835cc949","article-title":"Peroxisome proliferator-activated receptor delta: a multifaceted metabolic player","volume":"24","author":"Bojic","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/apt.13833-BIB0039|apt13833-cit-0039","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0040|apt13833-cit-0040","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0041|apt13833-cit-0041","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/apt.13833-BIB0042|apt13833-cit-0042","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0043|apt13833-cit-0043","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0044|apt13833-cit-0044","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/apt.13833-BIB0045|apt13833-cit-0045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/hep.21690","article-title":"Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis","volume":"46","author":"Soden","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0046|apt13833-cit-0046","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1080\/10715760500193820","article-title":"Vitamin E deficiency induces liver nuclear factor-kappaB DNA-binding activity and changes in related genes","volume":"39","author":"Morante","year":"2005","journal-title":"Free Radic Res"},{"key":"10.1111\/apt.13833-BIB0047|apt13833-cit-0047","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1196\/annals.1331.009","article-title":"Vitamin E mediates cell signaling and regulation of gene expression","volume":"1031","author":"Azzi","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/apt.13833-BIB0048|apt13833-cit-0048","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.cct.2016.02.012","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design","volume":"47","author":"Friedman","year":"2016","journal-title":"Contemp Clin Trials"},{"key":"10.1111\/apt.13833-BIB0049|apt13833-cit-0049","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cts.12397","article-title":"Pharmacokinetics, safety, and CCR2\/CCR5 antagonist activity of cenicriviroc in participants with mild or moderate hepatic impairment","volume":"9","author":"Lefebvre","year":"2016","journal-title":"Clin Transl Sci"},{"key":"10.1111\/apt.13833-BIB0050|apt13833-cit-0050","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nrgastro.2013.193","article-title":"Pharmacological agents for NASH","volume":"10","author":"Ratziu","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0051|apt13833-cit-0051","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.surg.2003.10.003","article-title":"Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis","volume":"135","author":"Kral","year":"2004","journal-title":"Surgery"},{"key":"10.1111\/apt.13833-BIB0052|apt13833-cit-0052","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/hep.20251","article-title":"Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss","volume":"39","author":"Dixon","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0053|apt13833-cit-0053","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"10.1111\/apt.13833-BIB0054|apt13833-cit-0054","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nri2449","article-title":"Nutrient sensing and inflammation in metabolic diseases","volume":"8","author":"Hotamisligil","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/apt.13833-BIB0055|apt13833-cit-0055","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/gut.2010.214577","article-title":"Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression","volume":"59","author":"Moschen","year":"2010","journal-title":"Gut"},{"key":"10.1111\/apt.13833-BIB0056|apt13833-cit-0056","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.trsl.2015.08.002","article-title":"Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence","volume":"167","author":"Federico","year":"2016","journal-title":"Transl Res"},{"key":"10.1111\/apt.13833-BIB0057|apt13833-cit-0057","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrgastro.2013.146","article-title":"The Gordian knot of dysbiosis, obesity and NAFLD","volume":"10","author":"Mehal","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0058|apt13833-cit-0058","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/MCG.0b013e31827873dc","article-title":"Immune therapy for nonalcoholic steatohepatitis: are we there yet?","volume":"47","author":"Ilan","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0059|apt13833-cit-0059","first-page":"141","article-title":"Intestinal permeability in non-alcoholic fatty liver disease: the gut-liver axis","volume":"9","author":"Scarpellini","year":"2014","journal-title":"Rev Recent Clin Trials"},{"key":"10.1111\/apt.13833-BIB0060|apt13833-cit-0060","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.3748\/wjg.v18.i21.2609","article-title":"Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis","volume":"18","author":"Ilan","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0061|apt13833-cit-0061","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.3748\/wjg.v20.i23.7381","article-title":"Role of gut microbiota and toll-like receptors in nonalcoholic fatty liver disease","volume":"20","author":"Miura","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0062|apt13833-cit-0062","first-page":"1077","article-title":"Gut barrier in health and disease: focus on childhood","volume":"19","author":"Viggiano","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1111\/apt.13833-BIB0063|apt13833-cit-0063","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1038\/cti.2015.47","article-title":"Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease","volume":"5","author":"Ilan","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"10.1111\/apt.13833-BIB0064|apt13833-cit-0064","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/imr.12194","article-title":"Intestinal dendritic cells in the regulation of mucosal immunity","volume":"260","author":"Bekiaris","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1111\/apt.13833-BIB0065|apt13833-cit-0065","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.gastro.2015.10.046","article-title":"Leukocyte trafficking to the small intestine and colon","volume":"150","author":"Habtezion","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0066|apt13833-cit-0066","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-065X.2011.01017.x","article-title":"Oral tolerance","volume":"241","author":"Weiner","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1111\/apt.13833-BIB0067|apt13833-cit-0067","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.humimm.2009.06.018","article-title":"Oral tolerance: can we make it work?","volume":"70","author":"Ilan","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1111\/apt.13833-BIB0068|apt13833-cit-0068","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-3542(00)00113-3","article-title":"Induction of oral tolerance towards hepatitis B envelope antigens in a murine model","volume":"48","author":"Gotsman","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1111\/apt.13833-BIB0069|apt13833-cit-0069","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1572-0241.2000.01935.x","article-title":"Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes","volume":"95","author":"Ilan","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0070|apt13833-cit-0070","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S1286-4579(03)00147-3","article-title":"Early expression of interferon gamma following oral antigen administration is associated with peripheral tolerance induction","volume":"5","author":"Kolker","year":"2003","journal-title":"Microbes Infect"},{"key":"10.1111\/apt.13833-BIB0071|apt13833-cit-0071","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.510290334","article-title":"Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model","volume":"29","author":"Trop","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0072|apt13833-cit-0072","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.3748\/wjg.v21.i18.5685","article-title":"Oral mixture of autologous colon-extracted proteins for the Crohn's disease: a double-blind trial","volume":"21","author":"Israeli","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0073|apt13833-cit-0073","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1756283X09351733","article-title":"Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease","volume":"3","author":"Israeli","year":"2010","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0074|apt13833-cit-0074","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1572-0241.2006.00441.x","article-title":"A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach","volume":"101","author":"Margalit","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0075|apt13833-cit-0075","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1478-3231.2004.0935.x","article-title":"Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial","volume":"24","author":"Israeli","year":"2004","journal-title":"Liver Int"},{"key":"10.1111\/apt.13833-BIB0076|apt13833-cit-0076","doi-asserted-by":"crossref","first-page":"9765","DOI":"10.1073\/pnas.0908771107","article-title":"Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob\/ob mice","volume":"107","author":"Ilan","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/apt.13833-BIB0077|apt13833-cit-0077","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/path.1869","article-title":"Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob\/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels","volume":"208","author":"Elinav","year":"2006","journal-title":"J Pathol"},{"key":"10.1111\/apt.13833-BIB0078|apt13833-cit-0078","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","article-title":"Etanercept: a review of its use in autoimmune inflammatory diseases","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1111\/apt.13833-BIB0079|apt13833-cit-0079","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrrheum.2014.106","article-title":"Advances in the management of psoriatic arthritis","volume":"10","author":"Olivieri","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"1 Suppl.","key":"10.1111\/apt.13833-BIB0080|apt13833-cit-0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/03946320140270S102","article-title":"Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab","volume":"27","author":"Armuzzi","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1111\/apt.13833-BIB0081|apt13833-cit-0081","doi-asserted-by":"crossref","first-page":"S 901 (A 2029)","DOI":"10.1016\/S0016-5085(14)63276-5","article-title":"A novel method for anti-TNF based-oral immunotherapy: oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating of Crohn's disease","volume":"146","author":"Shaaltiel","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0082|apt13833-cit-0082","first-page":"663A","article-title":"A novel method for anti-TNF based-oral immunotherapy: oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating of fatty liver disease","volume":"60","author":"Shaaltiel","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0083|apt13833-cit-0083","first-page":"S804 (A1881)","article-title":"Oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy","volume":"150","author":"Almon","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0084|apt13833-cit-0084","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jhep.2014.11.002","article-title":"Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity","volume":"62","author":"Anjani","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/apt.13833-BIB0085|apt13833-cit-0085","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/0006-2952(88)90271-7","article-title":"Glucosphingolipids as sites of action in the chemotherapy of cancer","volume":"37","author":"Radin","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/apt.13833-BIB0086|apt13833-cit-0086","doi-asserted-by":"crossref","first-page":"G917","DOI":"10.1152\/ajpgi.00105.2005","article-title":"Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes","volume":"289","author":"Margalit","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/apt.13833-BIB0087|apt13833-cit-0087","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/01.tp.0000252783.66886.f3","article-title":"Alleviation of acute and chronic graft-versus-host disease in a murine model is associated with glucocerebroside-enhanced natural killer T lymphocyte plasticity","volume":"83","author":"Ilan","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/apt.13833-BIB0088|apt13833-cit-0088","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.2006.095497","article-title":"Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders","volume":"56","author":"Zigmond","year":"2007","journal-title":"Gut"},{"key":"10.1111\/apt.13833-BIB0089|apt13833-cit-0089","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/icb.2009.42","article-title":"Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent","volume":"87","author":"Ilan","year":"2009","journal-title":"Immunol Cell Biol"},{"key":"10.1111\/apt.13833-BIB0090|apt13833-cit-0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/jpet.106.104950","article-title":"Glucocerebroside ameliorates the metabolic syndrome in OB\/OB mice","volume":"319","author":"Margalit","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/apt.13833-BIB0091|apt13833-cit-0091","first-page":"151","article-title":"Beta-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model","volume":"7","author":"Zigmond","year":"2014","journal-title":"J Inflamm Res"},{"key":"10.1111\/apt.13833-BIB0092|apt13833-cit-0092","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1152\/ajpendo.90634.2008","article-title":"Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat","volume":"296","author":"Zigmond","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/apt.13833-BIB0093|apt13833-cit-0093","first-page":"1046A","article-title":"Amelioration of hepatic fibrosis via beta-glucoslyceramide mediated immune modulation is associated with altered CD8 and NKT lymphoycte distribution","volume":"42","author":"Margalit","year":"2005","journal-title":"Hepatology"},{"issue":"Suppl 4","key":"10.1111\/apt.13833-BIB0094|apt13833-cit-0094","first-page":"200A","article-title":"Treatment of insulin resistance and non-alcoholic steatohepatitis by administration of beta glucosylceramide controlled trial","volume":"50","author":"Lalazar","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0095|apt13833-cit-0095","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/jf0009246","article-title":"Nutritional and health benefits of soy proteins","volume":"49","author":"Friedman","year":"2001","journal-title":"J Agric Food Chem"},{"key":"10.1111\/apt.13833-BIB0096|apt13833-cit-0096","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1056\/NEJM199508033330511","article-title":"Control of serum lipids with soy protein","volume":"333","author":"Erdman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/apt.13833-BIB0097|apt13833-cit-0097","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2337\/diacare.24.2.228","article-title":"Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects","volume":"24","author":"Hermansen","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/apt.13833-BIB0098|apt13833-cit-0098","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1080\/14786410701869598","article-title":"The effects of soy isoflavone on insulin sensitivity and adipocytokines in insulin resistant rats administered with high-fat diet","volume":"22","author":"Zhang","year":"2008","journal-title":"Nat Prod Res"},{"key":"10.1111\/apt.13833-BIB0099|apt13833-cit-0099","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1007\/s10620-006-9251-9","article-title":"Protective effect of soy isoflavones and activity levels of plasma paraoxonase and arylesterase in the experimental nonalcoholic steatohepatitis model","volume":"52","author":"Ustundag","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1111\/apt.13833-BIB0100|apt13833-cit-0100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2169\/internalmedicine1962.27.142","article-title":"Prevalence of fatty liver in a general population of Okinawa, Japan","volume":"27","author":"Nomura","year":"1988","journal-title":"Jpn J Med"},{"key":"10.1111\/apt.13833-BIB0101|apt13833-cit-0101","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.nut.2010.09.004","article-title":"Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis","volume":"27","author":"Yang","year":"2011","journal-title":"Nutrition"},{"key":"10.1111\/apt.13833-BIB0102|apt13833-cit-0102","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.3748\/wjg.v21.i24.7443","article-title":"Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance","volume":"21","author":"Khoury","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1111\/apt.13833-BIB0103|apt13833-cit-0103","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2174\/138945011796150343","article-title":"Understanding the use of immunosuppressive agents in the clinical management of IBD","volume":"12","author":"Waters","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1111\/apt.13833-BIB0104|apt13833-cit-0104","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.crohns.2011.12.003","article-title":"Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy","volume":"6","author":"Gilissen","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1111\/apt.13833-BIB0105|apt13833-cit-0105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2004.06.002","article-title":"Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial","volume":"127","author":"Hanauer","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0106|apt13833-cit-0106","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1111\/apt.13833-BIB0107|apt13833-cit-0107","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1053\/gast.2000.18144","article-title":"A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease","volume":"119","author":"Markowitz","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1111\/apt.13833-BIB0108|apt13833-cit-0108","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/cei.12640","article-title":"Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial","volume":"181","author":"Israeli","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/apt.13833-BIB0109|apt13833-cit-0109","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2249.2011.04511.x","article-title":"Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells","volume":"167","author":"Adar","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"Suppl.","key":"10.1111\/apt.13833-BIB0110|apt13833-cit-0110","first-page":"588A","article-title":"Alleviation of liver damage and hepatic fibrosis by oral administration of Imm 124 colostrums in Carbon tetrachloride (CCl4) model is mediated by decrease of hepatic F4\/80 macrophages activation","volume":"58","author":"Abd Alrahem","year":"2013","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0111|apt13833-cit-0111","first-page":"163A","article-title":"Alleviation of insulin resistance and liver damage by oral administration of etec colostrums is mediated by increased GLP-1, adiponectin serum levels and tregs: results of a phase I\/II clinical trial in NASH","volume":"52","author":"Mizrahi","year":"2010","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0112|apt13833-cit-0112","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nri1000","article-title":"CD3-specific antibody-induced active tolerance: from bench to bedside","volume":"3","author":"Chatenoud","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/apt.13833-BIB0113|apt13833-cit-0113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jns.2008.07.027","article-title":"New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity","volume":"274","author":"Ochi","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1111\/apt.13833-BIB0114|apt13833-cit-0114","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2337\/db06-1632","article-title":"Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody","volume":"56","author":"Ishikawa","year":"2007","journal-title":"Diabetes"},{"key":"10.1111\/apt.13833-BIB0115|apt13833-cit-0115","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nm1408","article-title":"Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells","volume":"12","author":"Ochi","year":"2006","journal-title":"Nat Med"},{"key":"10.1111\/apt.13833-BIB0116|apt13833-cit-0116","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0961203308100511","article-title":"Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells","volume":"18","author":"Wu","year":"2009","journal-title":"Lupus"},{"key":"10.1111\/apt.13833-BIB0117|apt13833-cit-0117","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.4049\/jimmunol.181.9.6038","article-title":"Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells","volume":"181","author":"Wu","year":"2008","journal-title":"J Immunol"},{"key":"10.1111\/apt.13833-BIB0118|apt13833-cit-0118","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10875-009-9323-7","article-title":"Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells","volume":"30","author":"Ilan","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1111\/apt.13833-BIB0119|apt13833-cit-0119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10875-015-0160-6","article-title":"Oral Administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial","volume":"35","author":"Lalazar","year":"2015","journal-title":"J Clin Immunol"},{"key":"10.1111\/apt.13833-BIB0120|apt13833-cit-0120","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fimmu.2015.00179","article-title":"The complex myeloid network of the liver with diverse functional capacity at steady state and in inflammation","volume":"6","author":"Eckert","year":"2015","journal-title":"Front Immunol"},{"key":"10.1111\/apt.13833-BIB0121|apt13833-cit-0121","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/apt.13833-BIB0122|apt13833-cit-0122","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0123|apt13833-cit-0123","first-page":"141","article-title":"Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I\/II clinical trial in NASH","volume":"5","author":"Mizrahi","year":"2012","journal-title":"J Inflamm Res"},{"key":"10.1111\/apt.13833-BIB0124|apt13833-cit-0124","first-page":"663","article-title":"A novel method for anti-TNF based-oral immunotherapy: oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating of fatty liver disease","volume":"60","author":"Shaaltiel","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/apt.13833-BIB0125|apt13833-cit-0125","first-page":"180A","article-title":"Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: a phase I\/II clinical study","volume":"44","author":"Zigmond","year":"2006","journal-title":"Hepatology"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.13833","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/apt.13833\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T17:26:49Z","timestamp":1625419609000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.13833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":125,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2016,12]]}},"URL":"https:\/\/doi.org\/10.1111\/apt.13833","archive":["Portico"],"relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,24]]}}}